Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.52 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | LAP3 | P28838 | 4/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659755 | 0.95 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8829767 | 0.91 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL664076 | 0.91 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL664033 | 0.91 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL13417428 | 0.91 | ALDH1A1 (0.48) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL10054696 | 0.91 | ALDH1A1 (0.48) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL664074 | 0.91 | CACNA2D1 (0.67) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL2693051 | 0.88 | CACNA2D1 (0.69) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL13978560 | 0.88 | CACNA2D1 (0.69) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL13855467 | 0.88 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268037-A | Asymmetric synthesis of - (+) -3- (aminomethyl) -5-methylhexanoic acid | TEVA PHARMA (IL) | 2008-09-17 | — | — | CN | claimed |
| CN-114164198-B | (R) - (-) -3- (carbamoylmethyl) -5-methylhexanoic acid synthetic protein, mutant and application thereof | 中国科学院微生物研究所 | 2025-01-07 | — | — | CN | disclosed |
| CN-110128293-B | Medical intermediate impurity and preparation method and application thereof | 武汉武药制药有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-111747862-A | Method for recovering pregabalin intermediate 3-isobutyl glutaric acid monoamide | 浙江华海药业股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-2916832-B1 | A PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LTD (IN) | 2019-01-16 | — | — | EP | disclosed |
| CN-102753702-B | Process for preparing optically active 3-substituted glutaric acid monoamides | KANEKA CORP | 2015-02-11 | — | — | CN | disclosed |
| EP-1841726-B1 | AN ASYMMETRIC SYNTHESIS OF (S)-(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | TEVA PHARMA (IL) | 2012-10-31 | — | — | EP | disclosed |
| CN-102753702-A | Process for preparing optically active 3-substituted glutaric acid monoamides | KANEKA CORP | 2012-10-24 | — | — | CN | disclosed |
| EP-2460885-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-SUBSTITUTED GLUTARIC ACID MONOAMIDE | Kaneka Corporation (JP) | 2012-06-06 | — | — | EP | disclosed |
| WO-2009001372-A2 | A NOVEL PROCESS FOR THE PREPARATION OF PREGABALIN | SATYANARAYANA REDDY MANNE (IN) | 2008-12-31 | — | — | WO | disclosed |
| CN-101268037-A | Asymmetric synthesis of - (+) -3- (aminomethyl) -5-methylhexanoic acid | TEVA PHARMA (IL) | 2008-09-17 | — | — | CN | disclosed |